Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 1
2021 pubmed

Expression of kisspeptin and KISS1 receptor in pituitary neuroendocrine tumours - an immunohistochemical study.

Mihajlovic. Milena M; Pekic. Sandra S; Doknic. Mirjana M; Stojanovic. Marko M; Miljic. Dragana D; Soldatovic. Ivan I; Vukotic. Tatjana T; Janev. Tijana T; Cirovic. Sanja S; Terzic. Tatjana T; Raicevic. Savo S; Skender-Gazibara. Milica M; Popovic. Vera V; Manojlovic-Gacic. Emilija E

Key Findings

  • Kisspeptin was found at low to moderate levels in most pituitary neuroendocrine tumors, with no strong staining.
  • There was no significant difference in kisspeptin levels between tumor types or compared to normal pituitary tissue.
  • The KISS1 receptor (KISS1R) was not detected in either the tumors or normal pituitary samples.

Practical Outcomes

  • For biohackers, this study doesn’t provide actionable guidance on kisspeptin supplementation or dosing. It suggests that, at least in pituitary tumors, kisspeptin’s role is unclear and the receptor may be absent, so any claims about anti‑cancer or performance benefits are not supported by this data.

Summary

Researchers looked at whether the hormone kisspeptin and its receptor are present in pituitary tumors. They found kisspeptin is weakly present in most tumors, but the receptor KISS1R was not detected at all. The study doesn’t give any new tips on using kisspeptin for health or performance.

Abstract

Pituitary neuroendocrine tumours (PitNETs), traditionally designated as pituitary adenomas, show elatively frequent invasive growth with exceptional metastatic potential, the causes of which are not entirely elucidated. Kisspeptins, which perform their activity through KISS1 receptor (KISS1R), are recognised as metastatic suppressors in many malignant tumours. This study aimed to investigate the immunohistochemical expression of kisspeptin and KISS1R in different types of PitNETs and to compare it with the expression in the normal anterior pituitary, using tissue microarray. The experimental group consisted of 101 patients with PitNETs, with 45 (37.3%) being of gonadotroph, 40 (33.9%) somatotroph, 4 (3.4%) corticotroph, 4 (3.4%) thyrotroph, 3 (2.5%) lactotroph, and 6 (5.1%) null-cell type. The control group consisted of anterior pituitary tissue accidentally removed during the surgery for PitNETs in 17 patients. Kisspeptin expression was observed in both experimental and control groups, without statistically significant differences in the staining intensity. Negative kisspeptin staining was detected in 10 (9.9%), weak in 79 (78.2%), and moderate in 12 tumours (11.9%); none of the tumours had strong staining intensity. The weak staining intensity was predominant in all PitNET types except thyrotroph tumours. Significant statistical difference in terms of kisspeptin expression between types of PitNET and the control group was not observed. Immunohistochemical expression of KISS1R was not observed in the control group or in the experimental group. We conclude that immunohistochemistry, as a method, cannot confirm the involvement of kisspeptin in tumourigenesis and aggressiveness of PitNETs, but potentially supports its antimetastatic role. The absence of KISS1R immunohistochemical expression in all anterior pituitaries and PitNETs in our cohort needs verification through the use of different procedures designed for the detection of the presence and localisation of proteins in the cell.

Study Information

Provider

pubmed

Year

2021

Date

2021-02-23T00:00:00.000Z

DOI

10.5603/ep.a2021.0009